Beyond KIR scaffolds, additional innate–derived receptor constructs, including those based on natural killer group 2 member D (NKG2D) and DNAX accessory molecule-1 (DNAM-1), have been engineered to exploit physiological tumor recognition pathways. This evidence concerns the gene CD226 and neoplasm.